Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules

Purpose: The impact of tertiary lymphoid structures (TLS) in hepatocellular carcinoma (HCC) progression is being extensively investigated. However, their presence during the early steps of human liver carcinogenesis remains unknown. We thus aimed to determine whether TLS are induced in preneoplastic/early hepatic lesions (EHL), and whether they are associated with a particular immune profile. Experimental Design: A series of 127 EHLs (low/high-grade dysplastic nodules, early HCC, and small and progressed HCC) was included in the study. TLSs were investigated by pathologic reviewing. Densities of immune cells were assessed using IHC. A subset of lesions was microdissected and gene expression profiling was performed with a custom NanoString panel. Results: Compared with surrounding cirrhotic nodules, EHL of all stages displayed increased densities of T cells, B cells, and dendritic cells. Immature TLSs were identified in 24% of EHL. Gene expression profiling identified a subset of EHL with elevated mRNA levels of various cytokines involved in immune cells' recruitment and TLS induction. This subgroup of EHL also showed overexpression of genes related to T- and B-cells' activation and antigen presentation, as well as those related to immunosuppression and immune exhaustion. Conclusions: Local immune activation occurs in the very early steps of liver carcinogenesis; however, it may not be fully efficient and paradoxically favor immune evasion and progression to full-blown HCC. These results have implications for the development of anti-HCC chemopreventive strategies in cirrhotic patients.

[1]  S. Friedman,et al.  An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. , 2019, Gastroenterology.

[2]  M. Ziol,et al.  Molecular and histological correlations in liver cancer. , 2019, Journal of hepatology.

[3]  C. Sautès-Fridman,et al.  Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.

[4]  A. Luciani,et al.  Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. , 2019, Journal of hepatology.

[5]  Y. Abe,et al.  Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification , 2018, Hepatology.

[6]  M. Roncalli,et al.  Phenotypic and molecular changes in nodule‐in‐nodule hepatocellular carcinoma with pathogenetic implications , 2018, Histopathology.

[7]  A. Luciani,et al.  Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance , 2018, Hepatology.

[8]  R. Stupp,et al.  Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer , 2017, Oncoimmunology.

[9]  Holger Moch,et al.  Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. , 2018, Cancer research.

[10]  Rohit Loomba,et al.  Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity , 2017, Nature.

[11]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[12]  M. Esteller,et al.  Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. , 2017, Gastroenterology.

[13]  A. Luciani,et al.  Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features , 2016, Hepatology.

[14]  E. Galun Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor‐promoting niche (TPN) in the development of hepatocellular carcinoma , 2016, Hepatology.

[15]  T. Ichikawa,et al.  Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. , 2016, Journal of hepatology.

[16]  K. Rajewsky,et al.  Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma , 2015, Nature Immunology.

[17]  J. Zucman‐Rossi,et al.  Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.

[18]  M. Karin,et al.  ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. , 2014, Cancer cell.

[19]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[20]  V. Sondak,et al.  12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.

[21]  T. Yeatman,et al.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.

[22]  M. Karin,et al.  NF-κB and STAT3 – key players in liver inflammation and cancer , 2011, Cell Research.

[23]  M. Kurrer,et al.  A lymphotoxin-driven pathway to hepatocellular carcinoma. , 2009, Cancer cell.

[24]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[25]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[26]  L. Terracciano,et al.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis , 2007, Hepatology.

[27]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[28]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[29]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[30]  T. Takahara,et al.  Functional B‐cell response in intrahepatic lymphoid follicles in chronic hepatitis C , 1999, Hepatology.

[31]  村上 純 Functional B cell response in intrahepatic lymphoid follicles in chronic hepatitis C , 1999 .

[32]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.